|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 328.16 USD | -0.93% |
|
-2.93% | -17.48% |
| 01-27 | Intellia gets FDA nod to resume one gene therapy trial after safety pause | RE |
| 01-20 | RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating | MT |
981.IowBdvRoZdRCAkNqwZzOpwYR3Di0j2WlQf6VoERtBX4.FONxQoIADpgqUBRfrcaA6mBpk1bZ2CvmEoT56BslZDRvym4FjBEwu3Uydw~67b43a104e236690a56ae781191a12e3
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition